Moleculin Biotech Inc (MBRX) Price Prediction & ForecastMBRXMoleculin Biotech Inc

Alphio's MBRX stock price prediction model matches the current Moleculin Biotech Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $8.95 (+0.85%). The 1-week path is $8.92 (+0.58%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Moleculin Biotech Inc (MBRX) is currently not a good buy due to significant risks despite some recent positive indicators. The current price is $8.87, which is drastically lower than the 52-week high of $253.05, indicating a substantial decline. The RSI is at 61.89, suggesting the stock is nearing overbought territory, while the forward P/E ratio is at 0, indicating uncertainty in future earnings. Furthermore, the company has reported a net income loss of $25,399,000 for Q3 2025, which raises concerns about its financial health. The primary risk is the company's cash position, with only $10.317 million available, which may not be sufficient for ongoing operations and trials, especially given the recent stock plunge of over 25% following clinical trial data.

Moleculin Biotech Inc (MBRX) last closed at $8.8699999, gaining +1.60%. These facts feed the 1-day and 1-week MBRX price prediction above.